Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy
This study is for patients with non-hodgkin's lymphoma or chronic lymphocytic leukemia, which
 has failed to shrink or has returned after previous treatment with chemotherapy. The purpose
 of this study is to find out whether patients with these types of cancer will have their
 tumor shrunk after treatment with a drug called Noscapine. The second purpose is to see what
 are the side effects of this drug. This drug is being used as an over-the-counter cough
 suppressor in Europe and Japan, but has also shown to be effective against cancer.
Inclusion Criteria:

 -  Patients with low grade NHL (follicular lymphoma, small cell lymphocytic lymphoma,
 marginal cell lymphoma, monocytoid B-cell lymphoma, MALT lymphoma, plasmacytoid
 lymphocytic lymphoma) or chronic lymphocytic leukemia who have demonstrated
 chemotherapy resistance (have not achieved CR,CRu, PR)or who have relapsed at any time
 following a response (CR, CRu, PR) after at least one therapy regimen, including
 chemotherapy, Rituximab, or high dose chemotherapy with stem cell rescue.

 -  Karnofsky performance status 60 % or greater.

 -  Creatinine less or equal to 2.0 mg/dl, bilirubin less or equal to 2.0 mg/dl, SGPT/SGOT
 less or equal to 4 x upper normal range

 Exclusion Criteria:

 -  Patients with unconfirmed complete response(CRu)after last treatment and who currently
 remain in CRu.

 -  Pregnant or lactating women.

 -  Disease-specific treatment less than 1 month prior to starting this study.

 -  CNS disease.

 -  HIV-positive patients.

 -  Other cancer, except basal cell or squamous cell cancer of the skin or carcinoma
 in-situ of cervix.